Search
Citations & References (39)
Invitrogen™
Lipofectamine™ RNAiMAX Transfection Reagent
Achieve effective RNAi transfection with Lipofectamine RNAiMAX Transfection Reagent across a wide range of cell types. This lipid-based transfection reagent is optimized for siRNA and miRNA transfection, offering high delivery efficiency and low cellular toxicity, enabling effective gene silencing.
Have Questions?
Change view
| Catalog Number | Quantity |
|---|---|
| 13778100 | 0.1 mL |
| 13778075 | 0.75 mL |
| 13778150 | 1.5 mL |
| 13778030 | 0.3 mL |
| 13778500 | 15 mL |
Catalog number 13778100
Price (KRW)
126,000
Online offer
Ends: 31-Dec-2025
140,000Save 14,000 (10%)
Each
Quantity:
0.1 mL
Price (KRW)
126,000
Online offer
Ends: 31-Dec-2025
140,000Save 14,000 (10%)
Each
Lipofectamine RNAiMAX reagent is a leading transfection reagent designed specifically for RNA interference applications. It efficiently delivers siRNA and miRNA into a wide variety of cell types, ensuring high transfection efficiency and effective gene knockdown. The proprietary cationic lipid formulation minimizes cytotoxicity, making it suitable for sensitive cells and long-term studies. Lipofectamine RNAiMAX reagent is optimized for consistent performance, providing researchers with reliable results in gene silencing experiments. Its ease of use and compatibility with high-throughput screening make it an essential tool for basic biology research and functional genomics.
Features of Lipofectamine RNAiMAX Transfection Reagent
- Optimized for RNAi—Specifically formulated for RNA interference applications, maximizing siRNA and miRNA transfection and gene silencing.
- Superior siRNA transfection efficiency—requires lower siRNA concentrations for effective gene knockdown
- miRNA reagent compatible—provides superior transfection efficiencies for miRNA mimics and inhibitors
- Minimal cytotoxicity—flexible 10-fold concentration range of the siRNA transfection reagent with low cellular impact
- Broad cell type compatibility—versatile use in a wide range of cell lines, including hard-to-transfect cells
- Simple and rapid protocol—easy-to-follow steps that save time and effort in the lab for consistent and reproducible results
High knockdown in a wide range of cells
Lipofectamine RNAiMAX Transfection Reagent is an effective siRNA transfection reagent suitable for a wide range of cell types, including primary cells (see figure). It achieves high-efficiency siRNA transfection, leading to significant gene knockdown necessary for convincing gene silencing results.
Simple, high-throughput-ready transfections
Mix Lipofectamine RNAiMAX Transfection Reagent with siRNA, add to your cells, incubate, and measure gene knockdown. Its simplicity and speed, combined with high transfection efficiency, make it ideal for high-throughput siRNA transfection workflows. Whether it's a forward or reverse transfection protocol, siRNA transfection conditions can be easily optimized for automated or robotic systems.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
For Use With (Application)Transfection
Green FeaturesSustainable packaging
High-throughput CompatibilityHigh-throughput Compatible
Product LineLipofectamine
Product TypeTransfection Reagent
Quantity0.1 mL
Serum CompatibleYes
Shipping ConditionApproved for shipment at Room Temperature or on Wet Ice
Cell TypeEstablished Cell Lines, Stem Cells, Primary Cells, Hard-to-Transfect Cells
Format6-well Plate, 12-well Plate, 24-well Plate, 48-well Plate, 96-well Plate, Flasks
Sample TypesiRNA, Synthetic siRNA, RNAi Plasmids (shRNA, miR), RNAi, miRNA
Transfection TechniqueLipid-based Transfection
Unit SizeEach
Contents & Storage
Each unit contains one vial of reagent. Store at 2–8°C.
Frequently asked questions (FAQs)
I'm seeing cell death after transfection using Lipofectamine RNAiMAX Reagent. What should I do?
I accidentally kept my Lipofectamine RNAiMAX Reagent at room temperature. Can I still use it?
I accidentally froze my Lipofectamine RNAiMAX Reagent. Can I still use it?
I accidentally left my lipid reagent at room temperature. Can I still use it?
What positive transfection control can I use with Lipofectamine RNAiMAX?
Citations & References (39)
Citations & References
Abstract
Journal:
PubMed ID:17804805
EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt.
Journal:Proc Natl Acad Sci U S A
PubMed ID:18093941
'The cadherin-catenin complex is the major machinery for cell-cell adhesion in many animal species. This complex in general associates with actin fibers at its cytoplasmic side, organizing the adherens junction (AJ). In epithelial cells, the AJ encircles the cells near their apical surface and forms the "zonula adherens" or "adhesion
Cytohesins are cytoplasmic ErbB receptor activators.
Journal:Cell
PubMed ID:20946980
'Signaling by ErbB receptors requires the activation of their cytoplasmic kinase domains, which is initiated by ligand binding to the receptor ectodomains. Cytoplasmic factors contributing to the activation are unknown. Here we identify members of the cytohesin protein family as such factors. Cytohesin inhibition decreased ErbB receptor autophosphorylation and signaling,
The spectrin cytoskeleton influences the surface expression and activation of human transient receptor potential channel 4 channels.
Journal:J Biol Chem
PubMed ID:18048348
'Despite over a decade of research, only recently have the mechanisms governing transient receptor potential channel (TRPC) channel function begun to emerge, with an essential role for accessory proteins in this process. We previously identified a tyrosine phosphorylation event as critical in the plasma membrane translocation and activation of hTRPC4
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.
Journal:Nature
PubMed ID:19078957
'BRAF and NRAS are common targets for somatic mutations in benign and malignant neoplasms that arise from melanocytes situated in epithelial structures, and lead to constitutive activation of the mitogen-activated protein (MAP) kinase pathway. However, BRAF and NRAS mutations are absent in a number of other melanocytic neoplasms in which